This paper provides a valuable observation that imiquimod, a compound often used to induce a psoriasis-like skin inflammation in mice, has a TLR7-independent effect acting through the unfolded protein ...
Johnson & Johnson's much-anticipated oral IL-23 inhibitor, icotrokinra, has claimed FDA approval as a first-line treatment for plaque psoriasis. The US regulator has approved icotrokinra under the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results